Compare OVID & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OVID | FLGT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.6M | 525.3M |
| IPO Year | 2017 | 2016 |
| Metric | OVID | FLGT |
|---|---|---|
| Price | $2.52 | $17.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $4.60 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 1.8M | 515.6K |
| Earning Date | 05-13-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,252,000.00 | ★ $18,730,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | $19.34 | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1181.27 | N/A |
| 52 Week Low | $0.27 | $13.46 |
| 52 Week High | $3.11 | $31.04 |
| Indicator | OVID | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 68.00 |
| Support Level | $2.33 | $13.91 |
| Resistance Level | $2.72 | $22.66 |
| Average True Range (ATR) | 0.16 | 0.65 |
| MACD | -0.01 | 0.24 |
| Stochastic Oscillator | 32.46 | 85.11 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.